Bioregulators: The Human Studies Used Animal Tissue Extracts. The Products Sold Are Synthetic Peptides.

The clinical literature behind peptide bioregulators is about Thymalin, Epithalamin, Cortexin and Retinalamin — extracts of calf thymus, bovine pineal gland, bovine brain cortex and cattle retina. Undefined polypeptide mixtures, registered as medicines in Russia.

The products sold under the "Khavinson peptides" name are Epitalon, Pinealon, Vesugen and Vilon — defined synthetic short peptides of two to four amino acids, made by solid-phase synthesis.

Those are not the same substances. Epitalon is a synthetic tetrapeptide designed from the pineal extract Epithalamin — a derivative, not the thing the mortality data was collected on. Most of what a buyer can purchase has never been studied in a human being at all.

No Khavinson bioregulator has ever been registered on ClinicalTrials.gov. Not one — we checked epitalon, epithalon, thymalin, cortexin and khavinson, and all five return totalCount = 0.

What are peptide bioregulators?

Peptide bioregulators are short peptides and tissue-derived polypeptide extracts developed from the 1970s onward at the St Petersburg Institute of Bioregulation and Gerontology, on the theory that specific tissues respond to specific short peptide signals that decline with age. Several are registered medicines in Russia under ATC code L03AX (other immunostimulants). None is approved in the United States, the European Union, or anywhere outside Russia and the CIS. The category is also referred to as cytomedines.

On Vladimir Khavinson himself, the facts are worth stating plainly and fairly, because dismissive coverage of this field usually gets them wrong.

He is a real and senior scientist. Doctor of Medical Sciences, Professor, and an Academician of the Russian Academy of Sciences. Director of the St Petersburg Institute of Bioregulation and Gerontology. President of the Gerontological Society of the Russian Academy of Sciences. Chief Scientific Researcher at the I.P. Pavlov Institute of Physiology. He served as President of the European Association of Gerontology and Geriatrics from 2011 to 2015 and subsequently on its executive committee.

His institute's own biography claims 1,050 scientific works, 31 monographs and 220 patents, and supervision of 76 dissertations. Those are self-published figures we could not independently corroborate, and we are reporting them as such. The RAS academician title and the EAGG presidency are the strongest and most checkable claims, and they are real.

None of that is in question. What is in question is whether the evidence supports what the compounds are sold to do — and that turns on a distinction the marketing does not make.

Which bioregulators are peptides, and which are animal tissue extracts?

The category contains two chemically unrelated classes, and the split runs almost exactly along the line dividing what has been studied in humans from what is sold to consumers. The extracts — Thymalin, Epithalamin, Cortexin, Retinalamin — are undefined polypeptide mixtures from animal glands, and they carry the Russian registrations and the clinical literature. The synthetics — Epitalon, Vilon, Pinealon, Vesugen — are defined short peptides of two to four residues, and they are what the research-peptide market actually ships.

Epitalon and Epithalamin are the case in miniature. Epithalamin is the bovine pineal extract that carries the mortality data. Epitalon is a four-residue synthetic peptide designed from it. They are related the way a drug is related to the plant it was isolated from — and the human cohort data was collected on the extract.

This has a hard consequence for verification. Mass spectrometry can confirm a synthetic tetrapeptide against a known mass. It cannot confirm an extract against anything, because there is no reference sequence, no target mass, and no authenticated standard. A "99% purity" figure on a Thymalin or Cortexin certificate is measuring peak area against no declared analyte — a category error, not a quality signal. See what HPLC testing can and cannot tell you.

One more distinction worth catching: Thymalin is not thymosin alpha-1. Thymosin alpha-1 is a defined 28-residue peptide of 3,108.3 Da with a CAS number, real approvals in around thirty countries, and a 1,106-patient double-blind trial. Thymalin is an undefined thymus extract. They come from the same organ and nothing else.

What the human evidence actually is

The entire human evidence base for bioregulator life extension is one cohort of 266 elderly people, observed for 6 to 8 years, who received the compounds during only the first 2 to 3 years. It reports mortality reductions of 2.0–2.1× for Thymalin, 1.6–1.8× for Epithalamin, 2.5× for the combination, and 4.1× in a subgroup treated annually for six years. The abstracts claim no randomisation, no placebo control and no blinding. No sample sizes per arm, event counts, confidence intervals or p-values are published.

And the two papers usually cited as separate studies are the same cohort, published twice.

Same two authors, same sample size, same observation period, same dosing schedule, same effect sizes, one year apart. Anyone citing "multiple studies" showing bioregulator life extension is counting one dataset twice.

A 4.1-fold mortality reduction without a denominator is not a result you can evaluate. It may be a real signal in a genuinely observed cohort — Soviet and post-Soviet clinical reporting conventions differed from Western ones, and absence of a p-value is not proof of absence of an effect. But it is not evidence that would pass a systematic review, and it is the sole human basis for the entire category.

The animal data is stronger and comes with a caveat. Anisimov, Mylnikov and Khavinson (Mechanisms of Ageing and Development, 1998, PMID 9701766) reported that epithalamin increased mean lifespan by 11–31% across fruit flies, C3H/Sn mice, LIO rats and SHR mice, with mortality-rate decreases of 52%, 27% and 52% in three of the four models. That is a real multi-species finding published in a legitimate journal — and Khavinson is a co-author, so it is not independent corroboration of his own human claims.

On telomeres, a 2025 cell-line paper reporting that epitalon lengthens telomeres through telomerase upregulation or ALT activity has since had a published correction (PMID 41240216, correcting PMID 40908429). Anyone citing the telomere result should cite the corrected version. Our Epithalon compound article covers that literature in detail.

Has anyone outside St Petersburg replicated this?

We could not find any independent replication of the human life-extension claim, and there is no registered clinical trial of any Khavinson bioregulator anywhere in the world. ClinicalTrials.gov returns totalCount = 0 for all five of epitalon, epithalon, thymalin, cortexin and khavinson — against 24 for tesamorelin on the same endpoint, so the search is working. A targeted literature search for epithalamin and thymalin in elderly mortality returned exactly two records: the two Khavinson and Morozov papers described above.

In every search we ran, the papers making substantive human or lifespan claims carry Khavinson, Morozov, Anisimov or Linkova as authors. That includes a 2021 Molecules paper titled "Peptide Regulation of Gene Expression: A Systematic Review" — which is itself Khavinson-authored, and is therefore a self-review rather than independent appraisal.

We want to be careful about the strength of this claim. Our searching was thorough but not exhaustive, and several bibliographic APIs were rate-limited during it. What we can say is: we found no independent replication, and we found no registered trial. Not that neither exists anywhere.

There is also no bioregulator-specific systematic review or critical appraisal that we could locate. A 2025 methodological appraisal of the DrugAge database found "significant shortcomings in reporting of crucial design features such as randomization and blinding" across 667 anti-ageing preclinical studies, and that only one third of non-mammal findings translated to mammals — but it does not name epithalamin or epitalon, and using it as a critique of bioregulators specifically would be a fabricated attribution.

What FDA found when it reviewed Epitalon

FDA's Pharmacy Compounding Advisory Committee reviewed Epitalon on 24 July 2026, nominated for insomnia at 10 mg/mL and 3000 mcg/mL by subcutaneous injection. FDA's own reviewers recommended against listing it, in writing: "we believe the evaluation criteria weigh against placing epitalon (free base) or epitalon acetate on the list of bulk drug substances that can be used to compound drug products."

The briefing document is the most thorough independent assessment of any bioregulator in existence, and its specifics matter.

On characterisation: epitalon is "not well-characterized," with "inconsistent naming conventions that do not follow established chemical nomenclature standards (e.g., INN, USAN, IUPAC)" and missing data on "peptide related impurities and aggregates, microbial quality (bioburden, bacterial endotoxins)."

On safety: "no clinical data to support the safety of epitalon… when used in humans."

On the telomerase mechanism — and this is the sentence that reframes the entire anti-aging pitch:

"epitalon has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer"

The mechanism the compound is sold on is the mechanism FDA flagged as a risk. Telomerase reactivation is a hallmark of malignant transformation, not only of cellular rejuvenation, and that tension is intrinsic to the target rather than a manufacturing problem.

On effectiveness for the nominated use: "we did not identify studies evaluating the use of these substances in patients with insomnia, particularly when administered via the proposed subcutaneous route." FDA located only a sublingual spray study measuring melatonin metabolites — not sleep outcomes.

The committee recommended listing it anyway, 7 in favour to 4 against with 1 abstention, reported by Hyman Phelps & McNamara's FDA Law Blog and Bass, Berry & Sims, whose published vote tables agree. That count needs one caveat: FDA has posted the agenda, roster, briefing documents, voting questions and slide decks for the meeting, but no minutes and no transcript — so every tally in circulation is press-derived rather than an agency document, and one trade outlet reports 7–5 against the law firms' 7–4. Epitalon was one of six affirmative recommendations across the two days; only emideltide (DSIP) was rejected.

Two corrections to how this is commonly reported, including on our own site. On the FDA bulk substances page current 22 April 2026, Epitalon sits in the table headed "Bulk drug substances nominated but withdrawn," introduced by FDA's own sentence: "This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators." That is a nominator's withdrawal, not a clearance — and our live Epithalon page currently describes it as having "achieved removal from FDA Category 2," which we are correcting.

FDA's retained safety language for Epitalon reads: "Compounded drugs containing epitalon may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA has not identified safety-related information regarding epitalon for the proposed route of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm if administered to humans."

Thymalin and the other bioregulators appear nowhere on FDA's compounding pages — they were never nominated, so they have never been evaluated. Semax, reviewed at the same meeting, went the other way procedurally, and our FDA peptide regulation timeline tracks where all of this lands.

On WADA: epitalon, epithalon, thymalin and cortexin do not appear on the 2026 Prohibited List. That is not the same as permitted — the S0 catch-all covers substances without approval from any governmental health authority, and the S2 lists are explicitly "including, but not limited to." Do not read absence as clearance.

If you are considering using them anyway — what verification can and cannot do

Verification works for the synthetics and fails for the extracts. Epitalon (AEDG) has a defined four-residue sequence and a known mass, so mass spectrometry confirms identity cleanly. Thymalin, Cortexin and Retinalamin have no reference sequence and no authenticated standard, so no test in this market distinguishes genuine registered extract from a different animal extract or a synthetic substitute. For those, endotoxin and sterility testing carry more weight than purity, because pyrogen contamination is the realistic failure mode for injectable animal-derived material.

The Purity Index records Epithalon at 99.41% across 242 independent tests across 227 verified shops, Pinealon at 99.54% across 63 tests, Vesugen at 99.66% across 18 tests, and Thymalin at 97.89% across 46 tests (verified August 2026). One Epithalon sample from July 2026 tested 44% over label — 14.4 mg in a vial marked 10 mg.

Peptigrity currently tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified 11 August 2026), with trust scores weighting community reviews and independently verified HPLC purity equally at 50% each.

Note what the table above implies about that Thymalin figure. It is the lowest purity score of any bioregulator we track — and it is also the number that means least, because it is a purity percentage on a substance with no declared analyte to be pure of.

Epithalon price data shows 57 shops in stock, median $3.80/mg, lowest $1.68/mg on a 50 mg vial, across 67 comparable offers (verified 8 August 2026). Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing. See where to buy Epitalon: purity and identity checks for the compound-specific checks, and compare across the family on the bioregulator category page.

The study that would settle this

The last row is the one that would change the category. Every mortality figure in circulation was collected on bovine gland extracts. Nobody has run the equivalent study on the synthetic peptides people actually inject.

Frequently Asked Questions

Are bioregulators peptides?

Some are and some are not. Epitalon, Vilon, Pinealon and Vesugen are defined synthetic short peptides of two to four amino acids. Thymalin, Epithalamin, Cortexin and Retinalamin are undefined polypeptide extracts from calf thymus, bovine pineal gland, bovine brain cortex and cattle retina. The human clinical literature is almost entirely about the extracts.

Is the life-extension study real?

There is one cohort: 266 elderly people observed over 6 to 8 years, dosed during the first 2 to 3 years, reporting mortality reductions of roughly two-fold. Its abstracts claim no randomisation, no placebo and no blinding, and report no sample sizes per arm, confidence intervals or p-values. It was published twice, in 2002 and 2003, by the same two authors — those are one study, not two.

Is Vladimir Khavinson a legitimate scientist?

Yes. He is an Academician of the Russian Academy of Sciences, director of the St Petersburg Institute of Bioregulation and Gerontology, and served as President of the European Association of Gerontology and Geriatrics from 2011 to 2015. His credentials are real; the question is whether the evidence supports the product claims.

Are there any clinical trials?

None registered. ClinicalTrials.gov returns zero results for epitalon, epithalon, thymalin, cortexin and khavinson. We found no independent replication of the human life-extension claim by any group outside the originating institute.

What did FDA say about Epitalon?

Its reviewers recommended against listing it for compounding, finding it "not well-characterized," with "no clinical data to support the safety of epitalon… when used in humans," and no studies of the nominated insomnia indication. FDA also noted that "epitalon has been shown to activate telomerase and lengthen telomeres, and longer telomeres are generally associated with increased risk for cancer." The advisory committee recommended listing it anyway, 7–4 with 1 abstention, per published law-firm vote tables; FDA itself released no minutes or transcript.

Is Thymalin the same as thymosin alpha-1?

No. Thymosin alpha-1 is a defined 28-residue peptide of 3,108.3 Da with a CAS number, approvals in a number of countries, and a 1,106-patient double-blind trial behind it. Thymalin is an undefined thymus extract with no sequence and no molecular weight. They share an organ of origin and nothing else.

Where this sits

The bioregulator category is not a fraud, and treating it as one misses what is actually wrong with it. A real institute, a real academician, real Russian registrations and a real 1998 multi-species lifespan paper sit behind it. What sits behind the human life-extension claim is one cohort of 266 people, published twice, with no randomisation and no denominators — and the compounds sold are mostly not the ones that cohort received.

The institute is real, its director is an academician of the Russian Academy of Sciences who led a European gerontology society, several of the extracts are registered medicines dispensed in Russian pharmacies, and the 1998 multi-species lifespan data was published in a legitimate journal. There is a genuine forty-year research programme here.

What that programme has not produced is a single registered clinical trial, any independent replication, any published composition for the extracts it is built on, or a controlled study of the synthetic peptides that are actually sold. The human life-extension evidence is one cohort of 266 people, reported without denominators, published twice.

And the substances differ. The mortality figures were collected on bovine pineal and thymus extracts. What ships to buyers is a synthetic tetrapeptide designed from one of them — cleanly verifiable by mass spectrometry, cheap at under two dollars a milligram, and never studied in a human under controlled conditions.

When FDA finally read the file on the best-known member of the family, it found the compound poorly characterised, the safety data absent, the nominated indication unstudied, and the signature mechanism — telomerase activation — associated with cancer risk rather than only with rejuvenation.

Browse the bioregulator peptides category, or our complete peptide guide with 118 compounds (verified August 2026). For per-injection volume on the synthetic bioregulators, use the peptide dosing calculator alongside the reconstitution calculator. Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.